Checkpoint blocking antibodies in cancer immunotherapy

FEBS Letters

Volumn 588, Issue 2, 2014, Pages 368-376

  Kyi, Chrisann ^a   Postow, Michael A ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Checkpoint blocking antibodies; Cytotoxic T lymphocyte antigen 4; Immunotherapy; Malignancy; Programmed death 1 receptor

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GLYCOPROTEIN GP 100; IPILIMUMAB; MEDI 4736; MK 3475; MPDL 3280A; NIVOLUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ANOREXIA; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; COLITIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; DERMATITIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOCRINE DISEASE; ENTEROCOLITIS; ESOPHAGUS CANCER; FATIGUE; HEMATOLOGIC MALIGNANCY; HEPATITIS; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFUSION RELATED REACTION; INNATE IMMUNITY; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; MESOTHELIOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; NAUSEA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERICARDIAL EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN LOCALIZATION; RASH; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOMA; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; THYROID DISEASE; VOMITING;

CHECKPOINT BLOCKING ANTIBODIES; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; IMMUNOTHERAPY; MALIGNANCY; PROGRAMMED DEATH-1 RECEPTOR;

ANIMALS; ANTIBODIES; ANTIGENS, CD274; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84892365940     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.10.015     Document Type: Review

References (94)

1. B. Fm The concept of immunological surveillance Prog. Exp. Tumor Res. 13 1970 1 27
2. G.P. Dunn, L.J. Old, and R.D. Schreiber The three Es of cancer immunoediting Annu. Rev. Immunol. 22 2004 329 360
3. M.K. Callahan, and J.D. Wolchok At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy J. Leukoc. Biol. 94 1 2013 41 53
4. K.E. de Visser, A. Eichten, and L.M. Coussens Paradoxical roles of the immune system during cancer development Nat. Rev. Cancer 6 1 2006 24 37
5. S.I. Abrams Regulation of tumor progression by anti-neoplastic T cell responses Cancer Biol. Ther. 3 2 2004 140 146
6. M.A. Caligiuri Human natural killer cells Blood 112 3 2008 461 469
7. O.J. Finn Immuno-oncology: understanding the function and dysfunction of the immune system in cancer Ann. Oncol. 23 Suppl. 8 2012 p. viii6-9
8. I. Melero et al. Immunostimulatory monoclonal antibodies for cancer therapy Nat. Rev. Cancer 7 2 2007 95 106
9. A.G. Baxter, and P.D. Hodgkin Activation rules: the two-signal theories of immune activation Nat. Rev. Immunol. 2 6 2002 439 446
10. M.K. Jenkins, and R.H. Schwartz Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo J. Exp. Med. 165 2 1987 302 319
11. K.J. Lafferty, and A.J. Cunningham A new analysis of allogeneic interactions Aust. J. Exp. Biol. Med. Sci. 53 1 1975 27 42
12. P. Bretscher, and M. Cohn A theory of self-nonself discrimination Science 169 3950 1970 1042 1049
13. A.M. Intlekofer, and C.B. Thompson At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy J. Leukoc. Biol. 94 1 2013 25 39
14. P.S. Linsley et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement Immunity 4 6 1996 535 543
15. M.C. Brunner et al. CTLA-4-mediated inhibition of early events of T cell proliferation J. Immunol. 162 10 1999 5813 5820
16. J.F. Brunet et al. A new member of the immunoglobulin superfamily-CTLA-4 Nature 328 6127 1987 267 270
17. E.A. Tivol et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 5 1995 541 547
18. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 5256 1996 1734 1736
19. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J. Exp. Med. 190 3 1999 355 366
20. F.S. Hodi et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 J. Clin. Oncol. 31 Suppl. CRA 9007 2013 (ASCO meeting abstracts June 2013)
21. F.S. Hodi et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 8 2010 711 723
22. C. Robert et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N. Engl. J. Med. 364 26 2011 2517 2526
23. P.A. Prieto et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin. Cancer Res. 18 7 2012 2039 2047
24. J.D. Wolchok et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol. 11 2 2010 155 164
25. C. Robert et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control Clin. Cancer Res. 19 8 2013 2232 2239
26. J.S. Weber, K.C. Kahler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J. Clin. Oncol. 30 21 2012 2691 2697
27. L.H. Camacho et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma J. Clin. Oncol. 27 7 2009 1075 1081
28. J.M. Kirkwood et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma Clin. Cancer Res. 16 3 2010 1042 1048
29. A. Ribas et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J. Clin. Oncol. 31 5 2013 616 622
30. C. Ralph et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma Clin. Cancer Res. 16 5 2010 1662 1672
31. P. Zatloukal et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients with advanced non-small cell lung cancer (NSCLC) J. Clin. Oncol. 27 Suppl. 8067 2009 (ASCO meeting abstracts May 2009)
32. K.Y. Chung et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer J. Clin. Oncol. 28 21 2010 3485 3490
33. S.L. Topalian et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 26 2012 2443 2454
34. Y. Ishida et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 11 11 1992 3887 3895
35. M. Ahmadzadeh et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 8 2009 1537 1544
36. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat. Rev. Immunol. 8 6 2008 467 477
37. R.H. Thompson et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc. Natl. Acad. Sci. USA 101 49 2004 17174 17179
38. B.A. Inman et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 8 2007 1499 1505
39. J. Hamanishi et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc. Natl. Acad. Sci. USA 104 9 2007 3360 3365
40. T. Nomi et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin. Cancer Res. 13 7 2007 2151 2157
41. C. Wu et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance Acta Histochem. 108 1 2006 19 24
42. H. Dong et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 8 2002 793 800
43. S. Wintterle et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis Cancer Res. 63 21 2003 7462 7467
44. J.A. Brown et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J. Immunol. 170 3 2003 1257 1266
45. J. Konishi et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin. Cancer Res. 10 15 2004 5094 5100
46. J. Liu et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood 110 1 2007 296 304
47. L. Xerri et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia Hum. Pathol. 39 7 2008 1050 1058
48. D.M. Dorfman et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma Am. J. Surg. Pathol. 30 7 2006 802 810
49. A. Rosenwald et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J. Exp. Med. 198 6 2003 851 862
50. H. Tamura et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia Clin. Cancer Res. 11 16 2005 5708 5717
51. Y. Iwai et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc. Natl. Acad. Sci. USA 99 19 2002 12293 12297
52. J. Nakanishi et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol. Immunother. 56 8 2007 1173 1182
53. R.H. Thompson et al. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma Urology 66 5 Suppl. 2005 10 14
54. H. Dong et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat. Med. 5 12 1999 1365 1369
55. G.J. Freeman et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J. Exp. Med. 192 7 2000 1027 1034
56. J. Zeng et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas Int. J. Radiat. Oncol. Biol. Phys. 86 2 2013 343 349
57. H. Nishimura et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 291 5502 2001 319 322
58. H. Nishimura et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 2 1999 141 151
59. M. Sznol et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) J. Clin. Oncol. 31 Suppl. CRA9006 2013 (ASCO meeting abstracts June 2013)
60. O. Hamid et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2 2013 134 144
61. R. Berger et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin. Cancer Res. 14 10 2008 3044 3051
62. J.R. Brahmer et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 26 2012 2455 2465
63. R.S. Herbst et al. al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors J. Clin. Oncol. 31 Suppl. 3000 2013 (ASCO meeting abstracts June 2013)
64. J.D. Wolchok et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin. Cancer Res. 15 23 2009 7412 7420
65. M. Nishino et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements Clin. Cancer Res. 19 14 2013 3936 3943
66. G.Y. Ku et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 7 2010 1767 1775
67. J. Delyon et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival Ann. Oncol. 24 6 2013 1697 1703
68. J.J. Luke et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience Cancer 119 20 2013 3687 3695
69. J. Yuan, M. Adamow, B.A. Ginsberg, T.S. Rasalan, E. Ritter, H.F. Gallardo, Y. Xu, E. Pogoriler, S.L. Terzulli, D. Kuk, K.S. Panageas, G. Ritter, M. Sznol, R. Halaban, A.A. Jungbluth, J.P. Allison, L.J. Old, J.D. Wolchok, and S. Gnjatic Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Proc. Natl. Acad. Sci. 108 2011 16723 16728
70. C.I. Liakou et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients Proc. Natl. Acad. Sci. USA 105 39 2008 14987 14992
71. B.C. Carthon et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin. Cancer Res. 16 10 2010 2861 2871
72. M.B. Atkins et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J. Clin. Oncol. 17 7 1999 2105 2116
73. S.F. Slovin et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 7 2013 1813 1821
74. M.F. Sprinzl, and P.R. Galle Facing the dawn of immunotherapy for hepatocellular carcinoma J. Hepatol. 59 1 2013 9 10
75. C. Genova et al. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer Expert Opin. Biol. Ther. 12 7 2012 939 948
76. R.E. Royal et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J. Immunother. 33 8 2010 828 833
77. J.F. Grosso, and M.N. Jure-Kunkel CTLA-4 blockade in tumor models: an overview of preclinical and translational research Cancer Immunol. 13 2013 5
78. J.C. Yang et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J. Immunother. 30 8 2007 825 830
79. S.F. Slovin et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann. Oncol. 24 7 2013 1813 1821
80. E.J. Small et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin. Cancer Res. 13 6 2007 1810 1815
81. J.D. Wolchok et al. Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2 2013 122 133
82. M.A. Postow et al. Immunologic correlates of the abscopal effect in a patient with melanoma N. Engl. J. Med. 366 10 2012 925 931
83. E.F. Stamell et al. The abscopal effect associated with a systemic anti-melanoma immune response Int. J. Radiat. Oncol. Biol. Phys. 85 2 2013 293 295
84. E. Simeone et al. Combination therapy with ipilimumab and electrochemotherapy: Preliminary efficacy results and correlation with immunologic parameters J. Clin. Oncol. 31 Suppl. e20031 2013 (ASCO meeting abstracts June 2013)
85. A. Boni et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res. 70 13 2010 5213 5219
86. D.T. Frederick et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clin. Cancer Res. 19 5 2013 1225 1231
87. J.S. Khalili et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma Clin. Cancer Res. 18 19 2012 5329 5340
88. C. Liu et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice Clin. Cancer Res. 19 2 2013 393 403
89. R.C. Koya et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy Cancer Res. 72 16 2012 3928 3937
90. A. Ribas et al. Hepatotoxicity with combination of vemurafenib and ipilimumab N. Engl. J. Med. 368 14 2013 1365 1366
91. A. Ribas Tumor immunotherapy directed at PD-1 N. Engl. J. Med. 366 26 2012 2517 2519
92. S.L. Topalian et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial J. Clin. Oncol. 31 Suppl. 3002 2013 (ASCO meeting abstracts June 2013)
93. J.R. Brahmer et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4358) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) J. Clin. Oncol. 31 Suppl. 8030 2013 (ASCO meeting abstracts June 2013)
94. C.G. Drake et al. Survival, safety, and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up J. Clin. Oncol. 31 Suppl. 4514 2013 (ASCO meeting abstracts June 2013)